Results 281 to 290 of about 355,709 (346)

Temporal trends in treatment-related cardiopulmonary disease-specific mortality in NSCLC based on pathological subtypes: a retrospective population-based cohort study. [PDF]

Ther Adv Med Oncol
Mo Y, Liang X, Wei D, Chen D, Yu J.
europepmc   +1 more source

Population Pharmacokinetic Analysis of Datopotamab Deruxtecan (Dato‐DXd), a TROP2‐Directed Antibody‐Drug Conjugate, in Patients With Advanced Solid Tumors

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Datopotamab deruxtecan (Dato‐DXd) is a trophoblast cell surface antigen 2 (TROP2)‐directed antibody‐drug conjugate (ADC) developed for the treatment of advanced or metastatic solid tumors. Dato‐DXd demonstrated promising antitumor activity and a manageable safety profile in the first‐in‐human Phase 1 study TROPION‐PanTumor01.
Ying Hong, Sophie Peigné, Υuzhuo Pan, Sofia Friberg Hietala, Anna McLaughlin, Naoyuki Tajima, Deise Uema, Hong Zebger‐Gong, Zoey Tang, Diansong Zhou, Malaz Abutarif, Τushar Garimella   +11 more
wiley   +1 more source

Brain metastasis-associated cancer fibroblasts drive tumor progression and therapeutic resistance through IL26 and CX3CL1 signaling in non-small-cell lung cancer. [PDF]

Exp Hematol Oncol
Salam SMA, Jahan E, Ahn EJ, Kim SS, Kim YJ, Park SJ, Jung TY, Kim IY, Jung S, Lee RJ, Lee JH, Rhee JH, Kim KK, Yi MH, Lee KH, Moon KS.   +15 more
europepmc   +1 more source

Model‐Informed Drug Development of Subcutaneous Nivolumab: Comparison of Pharmacokinetic Analysis Methodologies Using Clinical Trial Simulation

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT A subcutaneous formulation of nivolumab was evaluated in the phase III study CheckMate 67T (NCT04810078). The co‐primary pharmacokinetic exposure endpoints, time‐averaged serum concentration over the first 28 days (Cavgd28), and steady‐state trough concentration (Cminss) were determined through population pharmacokinetic analysis as compared ...
Yue Zhao, Heather Vezina, Zheyi Hu, Anna Kondic, Li Zhu, Amit Roy   +5 more
wiley   +1 more source

Are metformin-based combination approaches beneficial for non-small cell lung cancer: evidence from experimental and clinical studies. [PDF]

Mil Med Res
Thyagarajan A, Gajjar V, Sahu RP.
europepmc   +1 more source

Investigating the Potential of Curcumin in the Treatment of Nonsmall Cell Lung Cancer: A Systematic Review With Meta‐Analysis, Network Pharmacology, and Mendelian Randomization

Phytotherapy Research, EarlyView.
ABSTRACT To evaluate the efficacy and explore the potential mechanism of curcumin for the treatment and prevention of NSCLC. We searched six databases thoroughly for articles published before December 2024. Stata 15.0 software was applied for systematic review with meta‐analysis.
Yonglu Guo, Haohao Xu, Peng Shen, Ruijun Cai   +3 more
wiley   +1 more source

FGL1-mediated lymph node metastasis in stage T1 non-small cell lung cancer: therapeutic targeting. [PDF]

Exp Hematol Oncol
Tang XY, Zhang RZ, Feng ZB, Zhou YL, Du WG, Shu C, Shen Y, Li MC, Cai JC, Yan XL, Ma N, Zhao JB.   +11 more
europepmc   +1 more source

Jujuboside B Induces Ferroptosis and Overcomes Radioresistance Through the PPARγ‐ATF3‐Gpx4 Signaling Pathway in Non‐Small Cell Lung Cancer

Phytotherapy Research, EarlyView.
Jujuboside B induces ferroptosis and overcomes radioresistance. ABSTRACT Jujuboside B (JJB) is a saponin extracted from the Ziziphus jujuba var. spinose and has been reported to have anticancer effects. However, the detailed mechanism of its anti‐cancer effect in non‐small cell lung cancer (NSCLC) remains unclear.
Tae Woo Kim, Seong‐Gyu Ko
wiley   +1 more source

Sunvozertinib Monotherapy in Advanced Lung Adenocarcinoma with <i>EGFR</i> Exon 20 Insertion and High PD-L1 Expression: A Case Report. [PDF]

Cancer Manag Res
Zhou J, Han H.
europepmc   +1 more source

Unraveling the Metabolic Influence of Olfactory Receptors in Cancer Cells

Sensory Neuroscience, EarlyView.
ORs are aberrantly expressed in various tumor types and regulate cancer cell metabolism through nonclassical signaling pathways, including PI3K/Akt, MAPK, and ERK. These receptors influence tumor proliferation, invasion, and immune evasion. Specific OR–ligand interactions offer promising opportunities for targeted cancer therapy and early diagnosis ...
Chengzhilin Li, Xiaochen Gao, Ziheng Liu, Nianlei Zhang, Xue Cao, Wenwen Qi, Chengcheng Liu   +6 more
wiley   +1 more source